HealthScience and Research
MacroGenics reports 25% response in clear cell gynecologic cancer trial
Four of 16 evaluable patients responded to lorigerlimab as the company enrols a lower-dose cohort after significant treatment-related toxicity.
Pinnacle Silver and Gold receives permit for 110 El Potrero drill sites
Separate mine, plant, water and infrastructure approvals remain outstanding ahead of a targeted production decision in early 2027.
MiningFinancing
Blue Jay Gold plans C$3M Ocean Partners placement at C$0.90 a unit
Ocean Partners would own about 6.5 per cent before warrant exercise, with proceeds supporting Steller exploration and a study in the first half of 2027.
Analysis
Graphite One wins DLA carbon-materials award without disclosing value
The program will test domestic carbon composites for high-temperature defence systems, but payment terms and a testing deadline remain undisclosed.
Health
NASDAQ: ENTAEnanta Pharmaceuticals starts late-stage RSV trial with 2027 data due
RESOLVE will test symptom recovery and hospitalization in high-risk adults, starting with at least 200 patients in its Phase 2b portion.
MiningGold
Fury Gold Mines drills 14.95 g/t gold over 4.25m true width at Eau Claire
The intercept lies 60 metres up-dip from a historical hole inside the inferred resource, supporting plans to upgrade portions to indicated.
HealthScience and Research
BioNTech reports modest Phase 3 breast-cancer benefit and lung toxicity
The 541-patient DYNASTY-Breast02 trial met its primary endpoint, but the partners say potential patient benefit is limited.
Mining
ASX: RMLThree new holes support mineralisation to at least 300 metres depth, with more than 32 holes still awaiting complete assays.
Health
NASDAQ: BNTXPumitamig plus docetaxel showed early activity after immunotherapy and chemotherapy, but the Phase 2 study had no control arm.
Analysis
Summit Therapeutics reports 25% lower death risk in biliary-cancer trial
Ivonescimab plus chemotherapy extended median survival to 14.9 months in a China-only study, with a separate U.S. trial planned.
Latest
Alphabet's Google expands Voltus virtual power plant agreement to 1 GW
Google will fund flexible household and business resources in PJM, but the companies disclose no price or delivery schedule.
Pfizer details 25‑strain infant vaccine data as pivotal trials advance
A 401-infant presentation compared immune responses and safety with Prevnar 20; the company has not dated its pediatric Phase 3 readout.
Bitdeer Technologies Group sells all 283.4 BTC in weekly tally
Proprietary bitcoin holdings remained at zero as of Oct. 23, while the update omitted sale prices and cash proceeds.
Intelligent Protection Management agrees to buy AdTech business for up to US$2.7M
The California services acquisition would close in two stages, with cash, a seller note and an earnout subject to separate utility approvals.
Rock Tech Lithium starts Victory fieldwork ahead of 2027 drilling
Crews are assessing two undrilled occurrences and the corridor between them, with initial results expected in early 2027.
DiaMedica Therapeutics reaches 200 patients in pivotal stroke trial
An independent board will review ReMEDy2 in Q1 2027 and may resize the study to as many as 728 participants or stop it for futility.
Mentioned this week
Mining & Critical Minerals
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
MiningCopper
Teck Resources reports reduced capacity at Highland Valley as strike begins
USW Local 7619 represents about 1,200 workers at the B.C. copper operation, whose production loss has not been quantified.
Health & Science
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
Health
NASDAQ: XNCRSevere or worse treatment-related adverse events affected 72.1 per cent across expansion cohorts; FDA talks are planned for 2027.
Markets & Technology
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
CannabisStock News
Canopy Growth Corporation shareholders authorize up to 1‑for‑15 reverse split
Directors retain discretion over the ratio for common and exchangeable shares, with no effective date set in the voting disclosure.
Technology
NSE: STLTECHSterlite Technologies reports INR25.29B revenue and multiyear supply deals
A US$1.2 billion agreement spans 2026 to 2030, while a one-time tariff refund lifted the September quarter’s reported earnings.
Energy
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
Energy
NYSE: AESIThe delayed draw facility starts with US$171 million borrowed and a 180-day maturity, with an extension tied to supply agreements and lender consent.
Energy
LON: IESThe National Wealth Fund is providing £12.2 million, with admission targeted for Nov. 12 subject to shareholder approval.
Energy
NASDAQ: NNEAn initial study is estimated at six months; NANO disclosed no retainer amount, fabrication price or component delivery date.
Cannabis & Psychedelics
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
Psychedelics
CNSX: OPTIThe capsules are intended for three programs, including a Canadian Phase 3 PTSD trial of up to 100 people expected to begin in 2027.
Cannabis
TSE: OGIThe province estimates illegal retailers take 30 per cent of cannabis sales and proposes inspection, seizure and penalty powers for the AGCO.
Cannabis
TSE: CURAThe bid offers US$1 in cash plus 0.4013 Curaleaf shares for each Aurora share, with a Dec. 4 tender deadline.
Cannabis
TSE: CRONCash earnouts tied to 2026 and 2027 earnings add to the base price for a grower supplying nearly all 69 shops in the Dutch pilot.